Every Form 4 that CervoMed (CRVO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CRVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRVO filings page.
CervoMed Inc. director-associated trusts participated in a significant private placement. On June 11, 2026, the Joshua S. Boger 2021 Trust purchased 955,414 units at $3.14 per unit in a private placement, each unit consisting of one share of common stock plus one Series B warrant and one Series C warrant.
The Series B warrants have a $3.32 exercise price and expire five years from issuance, while the Series C warrants have a $3.14 exercise price and expire one year from issuance. After these transactions, trusts for which Joshua S. Boger is sole trustee hold 1,600,117 and 195,748 common shares, respectively, though he disclaims beneficial ownership of these securities.
CervoMed Inc. director Frank Zavrl received a grant of stock options as part of his non-employee director compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of common stock at an exercise price of $2.91 per share under the 2025 Equity Incentive Plan. These options vest monthly in substantially equal 1/12th increments over one year beginning June 30, 2026, contingent on his continued board service. Following this grant, Zavrl holds 8,150 stock options directly.
CervoMed Inc. director Marwan Sabbagh reported receiving a grant of stock options as part of his board compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share. These options were granted under the company’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The options vest in substantially equal monthly installments over one year, with 1/12 of the underlying shares vesting on the last day of each month beginning June 30, 2026, contingent on his continued board service.
CervoMed Inc. director David Quigley received a stock option grant as part of his compensation for joining the board. On June 8, 2026, he was awarded options to buy 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share, expiring on June 8, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan and its non-employee director compensation policy. The underlying shares vest in substantially equal 1/12 monthly installments over one year, starting June 30, 2026, subject to his continued board service.
CervoMed Inc. reported that director Jeffrey V. Poulton received a stock option award tied to his election to the board. On June 8, 2026, he was granted options to purchase 8,150 shares of CervoMed common stock at an exercise price of $2.91 per share.
The award was granted under CervoMed’s 2025 Equity Incentive Plan pursuant to its non-employee director compensation policy. The underlying shares vest in substantially equal monthly installments over one year, with 1/12 of the award vesting on the last day of each month beginning on June 30, 2026, subject to his continued service.
CervoMed Inc. director Jane H. Hollingsworth received a stock option grant tied to her election to the board. The award covers 8,150 shares of CervoMed common stock with an exercise price of $2.91 per share and expires on June 8, 2036.
The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares vest monthly over one year in substantially equal 1/12th increments on the last day of each month beginning on June 30, 2026, contingent on continued board service.
CervoMed Inc. director and 10% owner Sylvie Gregoire received a stock option grant related to her election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share and expires on June 8, 2036. The option was granted under CervoMed’s 2025 Equity Incentive Plan in line with its non-employee director compensation policy. The underlying shares will vest in 12 equal monthly installments on the last day of each month starting June 30, 2026, contingent on her continued board service.
CervoMed Inc. director and 10% owner Joshua S. Boger received a stock option grant in connection with his election to the board. The award covers 8,150 shares of common stock at an exercise price of $2.91 per share, expiring on June 8, 2036. These shares vest in substantially equal monthly installments over one year starting on June 30, 2026, conditioned on his continued board service.
CervoMed Inc. reported an insider equity award linked to its CEO and President, John J. Alam. The Form 4 shows a grant of stock options covering 8,150 shares of common stock at an exercise price of $2.91 per share, held indirectly through his spouse.
The options were granted to Dr. Sylvie Gregoire, a non-employee director and spouse of the reporting person. The filing states that Alam disclaims beneficial ownership of these securities. The underlying shares vest monthly over one year in substantially equal 1/12 increments, beginning on June 30, 2026, subject to Dr. Gregoire’s continued service.
CervoMed Inc. reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options. On February 11, 2026, he was awarded options to acquire 30,000 shares of CervoMed common stock at an exercise price of $4.8 per share.
The award vests in 36 roughly equal monthly installments, with vesting starting on February 28, 2026 and continuing on the last calendar day of each month over three years. All 30,000 derivative securities are reported as directly owned following this grant.
CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire. A derivative position of 75,000 stock options with a $4.80 exercise price was granted on February 11, 2026 to her spouse, John Alam, the company’s President & Chief Executive Officer.
The options relate to 75,000 shares of common stock and were reported at a cost of $0 for the derivative itself, with 75,000 derivative securities beneficially owned after the transaction as indirect ownership "By Spouse." The filing states that Gregoire disclaims beneficial ownership. The underlying shares will vest in 36 monthly installments beginning February 28, 2026.
ELDER WILLIAM ROBERT reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
De Rosch Mark reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
Blackburn Kelly reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
ALAM JOHN J reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.
CervoMed Inc. officer reports open-market stock purchases
An officer of CervoMed Inc. (CRVO), serving as Chief Commercial and Business leader, reported buying company common stock in open-market transactions. On 11/17/2025, the officer purchased 3,500 shares at a price of $8.43 per share. On 11/18/2025, the officer purchased an additional 1,500 shares at $7.95 per share.
After these transactions, the officer beneficially owns a total of 15,000 shares of CervoMed common stock, held directly. The filing indicates that the reported transactions were regular stock purchases rather than option exercises or other derivative security activity.
CervoMed Inc. (CRVO) director and 10% owner reported open‑market purchases of common stock. On 11/17/2025, the reporting person bought 10,793 shares of CervoMed common stock at a weighted average price of $8.46 per share in open‑market transactions. On the same date, an additional 10,807 shares were purchased at a weighted average price of $8.46 per share in an individual retirement account held by the reporting person’s spouse. After these transactions, the reporting person beneficially owned 1,484,078 shares directly and 12,500 shares indirectly through the spouse’s IRA, including shares jointly held with the issuer’s President & Chief Executive Officer.
CervoMed Inc. (CRVO) reported insider share purchases by a senior executive. The company’s CFO, General Counsel and Secretary bought 1,000 shares of common stock on 11/17/2025 at $8.45 per share and 2,500 shares on 11/18/2025 at a weighted average price of $8.32 per share in open‑market transactions. Following these transactions, the reporting person beneficially owned 12,500 shares of CervoMed common stock directly.
The filing notes that the 2,500 shares purchased on 11/18/2025 were acquired at prices ranging from $8.26 to $8.38, with the weighted average price reported, and that detailed trade breakdowns are available upon request.
CervoMed Inc. (CRVO) reported insider share purchases by its CEO & President, who is also a director and 10% owner. On 11/17/2025, the reporting person bought 10,807 shares of common stock in open‑market transactions at a weighted average price of $8.46, with actual prices ranging from $8.39 to $8.46. Following this, the reporting person directly beneficially owned 1,484,078 shares.
On the same date, an additional 10,793 shares were purchased at a weighted average price of $8.46 (with prices from $8.38 to $8.50) for the reporting person’s spouse’s IRA, which is reported as indirect ownership of 12,500 shares. The ownership totals also include shares held jointly with the spouse and in a Roth IRA.
CervoMed Inc. (CRVO) reported insider share purchases by a major holder. A director and 10% owner bought 4,447 shares of common stock on 11/13/2025 at $7.51 per share in open-market transactions. On 11/14/2025, additional purchases included 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA and 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA.
After these transactions, the reporting person beneficially owned 1,471,578 shares of CervoMed common stock directly, with 1,693 shares held indirectly through a spouse's IRA. Some shares are held jointly with the reporting person's spouse, Dr. John Alam, the company's President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported insider buying by its CEO, President, director and 10% owner. On 11/13/2025, the reporting person bought 4,447 shares of common stock in open-market transactions at $7.51 per share. On 11/14/2025, additional open-market purchases included 1,693 shares at a weighted average price of $7.55 through the John J. Alam Roth IRA and 1,707 shares at a weighted average price of $7.57 through the Sylvie Gregoire Roth IRA. Following these transactions, 1,471,578 shares were held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, with separate Roth IRA holdings noted.
CervoMed Inc. (CRVO) reported an insider transaction in which its Chief Commercial and Business officer purchased 10,000 shares of common stock in open-market transactions on 11/14/2025 at a weighted average price of $7.57 per share. Following this transaction, the reporting person beneficially owns 10,000 shares, held directly.
According to the filing, the shares were bought in multiple open-market trades at prices ranging from $7.53 to $7.60 per share. The reporting person has undertaken to provide full details of the number of shares purchased at each separate price within this range upon request.
CervoMed Inc. (CRVO) reported an insider transaction on a Form 4. A director and 10% owner purchased 5,553 shares of common stock in open‑market transactions on 11/12/2025 at a price of $7.35 per share. Following the purchase, the reporting person beneficially owned 1,467,131 shares. The filing notes these shares are held jointly with the reporting person’s spouse, Dr. John Alam, M.D., the company’s President & Chief Executive Officer and a member of the Board of Directors.
CervoMed Inc. (CRVO) reported an insider stock purchase by its CFO, GC & Secretary, William R. Elder. On 11/12/2025, Elder bought 3,500 shares of common stock in open‑market transactions at $7.44 per share (Transaction Code: P). Following the transaction, his direct holdings total 9,000 shares. The filing was submitted by one reporting person.
CervoMed Inc. (CRVO) insider purchase: The CEO & President, who is also a Director and 10% Owner, bought 5,553 shares of common stock at $7.35 on 11/12/2025 in open‑market transactions. Following the purchase, he beneficially owned 1,467,131 shares, reported as directly held. The filing notes these shares are held jointly by the reporting person and his spouse, Dr. Sylvie Gregoire, PharmD, a member of the Board of Directors.
CervoMed Inc. reported a Form 4 showing that Matthew Winton, serving as Chief Commercial and Business Officer and a director-level officer, received a grant of 75,000 stock options as an inducement award tied to his employment. The options have an exercise price of $8.62 and were issued with an acquisition date of 10/06/2025. The award vests in equal monthly installments over 36 months, beginning on 10/31/2025, and the option term extends to 10/06/2035. The filing was signed on 10/07/2025.